The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: Phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486

Cancer

Volumn 86, Issue 6, 1999, Pages 957-968

  Oken, Martin M ^a,e   Leong, Traci ^b   Lenhard Jr , Raymond E ^c   Greipp, Philip R ^d   Kay, Neil E ^a   Van Ness, Brian ^e   Keimowitz, Rudolph M ^f   Kyle, Robert A ^d  

^a Virginia Piper Cancer Institute   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f GUNDERSEN LUTHERAN MEDICAL CENTER   (United States)

Author keywords

Complete remission; Interferon; Multiple myeloma; Randomized clinical trial; Survival

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN LIGHT CHAIN; M PROTEIN; MELPHALAN; PREDNISONE; RECOMBINANT ALPHA2 INTERFERON; VINCRISTINE;

ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARDIOVASCULAR DISEASES; CARMUSTINE; CYCLOPHOSPHAMIDE; HEMATOLOGIC DISEASES; HUMANS; INFECTION; INTERFERON TYPE I, RECOMBINANT; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; PREDNISONE; SURVIVAL ANALYSIS; VINCRISTINE;

EID: 0033567902     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990915)86:6<957::AID-CNCR10>3.0.CO;2-8     Document Type: Article

References (63)

1. Alexanian R, Bonnet M, Gehan E, Haut A, Hewlett J, Lane M, et al. Combination therapy for multiple myeloma. Cancer 1972;30:382-9.
2. Oken MM. Standard treatment of multiple myeloma. Mayo Clin Proc 1994;69:781-6.
3. Costa G, Engle RL Jr., Schilling A, Carbone P, Kochwa S, Nachman R, et al. Melphalan and prednisone: an effective combination for the treatment of multiple myeloma. Am J Med 1973;54:589-99.
4. Bergsagel DE, Bailey AJ, Langley GR, MacDonald RN, White DF, Miller AB. The chemotherapy of plasma-cell myeloma and the incidence of acute leukemia. N Engl J Med 1979;301: 743-8.
5. Case DC Jr., Lee BJ III, Clarkson BC. Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol. Am J Med 1977;63:897-903.
6. MacLennan IC, Chapman C, Dunn J, Kelly K. Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. Lancet 1992;339:200-5.
7. Salmon SE, Tesh D, Crowley J, Saeed S, Finley P, Milder MS, et al. Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study. J Clin Oncol 1990; 8:1575-84.
8. Durie BG, Dixon DO, Carter S, Stephens R, Rivkin S, Bonnet J, et al. Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group study. J Clin Oncol 1986;4:1227-37.
9. Salmon SE, Haut A, Bonnet JD, Amare M, Weick JK, Durie BGM, et al. Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: a Southwest Oncology Group study. J Clin Oncol 1983;1:453-61.
10. Oken MM, Tsiatis A, Abramson N, Glick J. Comparison of standard with intensive therapy for the treatment of multiple myeloma [Abstract 1055]. Proc Am Soc Clin Oncol 1984; 3:270.
11. Oken MM, Harrington DP, Abramson N, Kyle RA, Knospe W, Glick JH. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479. Cancer 1997;79:1561-7.
12. Gutterman JU, Blumenschein GR, Alexanian R. Leukocyte interferon-induced regression in human metastatic breast cancer, multiple myeloma and malignant lymphoma. Ann Intern Med 1980;9:399-406.
13. Mellstedt H, Aahre A, Bjorkholm M, Johansson B, Strander H, Brenning G, et al. Interferon therapy of patients with myeloma. In: Terry W, Rosenberg S, editors. Immunotherapy of human cancer. New York: Elsevier North Holland, Inc., 1982:387-91.
14. Ahre A, Bjorkholm M, Mellstedt H, Brenning G, Engstedt L, Gahrton G, et al. Human leukocyte interferon and intermittent high-dose melphalan-prednisone administration in the treatment of multiple myeloma: a randomized clinical trial from the Myeloma Group of Central Sweden. Cancer Treat Rep 1984;68:1331-8.
15. Ludwig H, Cortelezzi A, Van Camp BGK, Polli E, Scheithauer W, Kuzmits R, et al. Treatment with recombinant interferon-alpha-2C: multiple myeloma and thrombocythaemia in myeloproliferative diseases. Oncology 1985;4:19-25.
16. Wagstaff J, Loynds P, Scarffe JH. Phase II study of rDNA human alpha-2 interferon in multiple myeloma. Cancer Treat Rep 1985;69:495-8.
17. Ohno R, Kimura K. Treatment of multiple myeloma with recombinant interferon alfa-2a. Cancer 1986;57:1685-8.
18. Quesada JR, Alexanian R, Hawkins M, Barlogie B, Borden E, Itri L, et al. Treatment of multiple myeloma with recombinant alpha interferon. Blood 1986;67:275-8.
19. Oken MM, Kyle RA, Kay NE, Greipp PR, O'Connell MJ. Interferon in the treatment of refractory multiple myeloma: an Eastern Cooperative Oncology Group study. Leuk Lymphoma 1990;1:95-100.
20. α2b) in patients with multiple myeloma. Leuk Lymphoma 1996;20:447-52.
21. Lenhard RE, Oken MM, Barnes JM, Humphrey RL, Glick JH, Silverstein MN. High-dose cyclophosphamide: an effective treatment for advanced refractory multiple myeloma. Cancer 1984;53:1456-60.
22. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5:649-55.
23. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Cancer 1975;36:842-54.
24. Due J, Morel B, Peitrequin R, Frei PC. Identification of monoclonal gammopathies: a comparison of immunofixation immunoelectrophoresis and measurements of kappa and lambda immunoglobulin levels. J Clin Lab Immunol 1988;2:141-6.
25. Mehta CR, Patel NR. A network algorithm for performing Fisher's exact test in rxc contingency tables. J Am Stat Assoc 1983;78:427-34.
26. Cox DR, Snell EJ. Analysis of binary data. London: Chapman and Hall, 1970.
27. Lehmann EL. Nonparametrics: statistical methods based on ranks. San Francisco: Holden-Day, 1975.
28. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
29. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc A 1972;135:185-206.
30. Cox DR. Regression models and life tables. J R Stat Soc B 1972;34:187-220.
31. Greipp PR, Oken MM, Kalish LA, Miller AM, Kyle RA. Independent prognostic value for plasma cell labeling index (PCLI) and beta 2-microglobulin (B2M) in Eastern Cooperative Oncology Group trial E9487 [Abstract 1227]. Proc Am Soc Clin Oncol 1992;11:357.
32. Greipp PR, Gaillard JP, Kalish LA, Oken MM, Miller AM, Kyle RA, et al. Independent prognostic value for serum soluble interleukin-6 (sIL-6R) in Eastern Cooperative Oncology Group myeloma trial E9487 [Abstract 1384]. Proc Am Soc Clin Oncol 1993;12:404.
33. Greipp PR, Gaillard JP, Klein B, Oken MM, Kalish L, Leong T, et al. Independent prognostic value for plasma cell labeling index, immunofluorescence microscopy plasma cell percent, beta 2-microglobulin, soluble interleukin-6 receptor and C-reactive protein in Myeloma Trial E9487 [Abstract 1524]. Blood 1994;84(Suppl 1):385a.
34. Oken MM. Multiple myeloma: prognosis and standard treatment. Cancer Invest 1997;15:57-64.
35. Liu P, Leong T, Quam L, Billadeau D, Kay NE, Greipp P, et al. Activating mutations of N-and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III trial. Blood 1996;88: 2699-706.
36. Greipp PR, Bennett JM, Gaillard JP, Klein B, Leong T, Oken MM, et al. Poor survival in plasmablastic myeloma in Eastern Cooperative Oncology Group study E9487. Cell kinetic, ploidy, biological marker and clinical correlations [Abstract 1355]. Proc Am Soc Clin Oncol 1995;14:426.
37. Greipp PR, Leong T, Bennett JM, Gaillard JP, Klein B, Oken MM, et al. Plasmablastic myeloma response and survival in Phase III clinical trial E9486: an Eastern Cooperative Oncology Group (ECOG) Myeloma Laboratory Study Group report [Abstract 1390]. Proc Am Soc Clin Oncol 1996;15:446.
38. Kay NE, Oken MM, Bone N, Kyle RA, Greipp P, Van Ness B, et al. Circulating CD19+ cell levels in myeloma. Blood 1995; 86:4000.
39. Kay N, Leong T, Van Ness B, Oken M, Greipp P, Bone N, et al. Circulating CD19+ blood cells in multiple myeloma: phenotypic and molecular analysis of ECOG trial E9486/ 9487 [Abstract 1088]. Blood 1995;86(Suppl 1):275a.
40. Oken MM, Pomeroy C, Weisdorf D, Bennett JM. Prophylactic antibiotics for the prevention of early infection in multiple myeloma. Am J Med 1996;100:624-8.
41. Kay NE, Oken MM, Bone N, Kyle RA, Van Ness B. Detection of clonally expanded blood T-cell populations in multiple myeloma patients [Abstract 1019]. Blood 1993;82(Suppl 1): 258a.
42. Kay NE, Bone N, Leong T, Oken MM, Kyle RA, Greipp PR, et al. Alteration of T Helper subsets in multiple myeloma patients at diagnosis and with therapy [Abstract 1352]. Proc Am Soc Clin Oncol 1995;14:425.
43. Billadeau D, Blackstadt M, Greipp P, Kyle RA, Oken MM, Kay N, et al. Analysis of B-lymphoid malignancies using allele-specific polymerase chain reaction: a technique for sequential quantitation of residual disease. Blood 1991;78:3021-9.
44. Billadeau D, Quam L, Thomas W, Kay N, Greipp P, Kyle R, et al. Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma patients. Blood 1992; 80:1818-24.
45. Attal M, Harousseau J-L, Stoppa A-M, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996;335:91-7.
46. Ludwig H, Cortelezzi A, Scheithauer W, van Camp BCK, Kuznits R, Fillet G, et al. Recombinant interferon alfa-2c versus polychemotherapy (VMCP) for treatment of multiple myeloma: a prospective randomized trial. Eur J Cancer Clin Oncol 1986;22:1111-6.
47. Mellstedt H, Osterborg A, Bjorkholm M, Bjoreman M, Brenning G, Gahrton G, et al. Treatment of multiple myeloma with interferon alpha: the Scandinavian experience. Br J Haematol 1991;79(Suppl 1):21-5.
48. Osterborg A, Bjorkholm M, Bjoreman M, Brenning G, Carlson K, Celsing F, et al. Natural interferon-alpha in combination with melphalan/prednisone versus melphalan/prednisone if the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden. Blood 1993;81:1428-34.
49. Lenhard RE Jr., Kalish LA, Oken MM, Ettinger DS, Glick J. Timed-sequential high-dose cyclophosphamide and vincristine in the treatment of multiple myeloma. Cancer 1994; 73:2113-8.
50. Lenhard RE, Daniels MJ, Oken MM, Glick JH, Ettinger DS, Kalish L, et al. An aggressive high dose cyclophosphamide and prednisone regimen for advanced multiple myeloma. Leuk Lymphoma 1994;13:485-9.
51. Cunningham D, Paz-Ares L, Gore ME, Malpas J, Hickish T, Nicolson M, et al. High-dose melphalan for multiple myeloma: long-term follow-up data. J Clin Oncol 1994;12: 764-8.
52. Barlogie B, Jagannath S, Vesole D, Tricot G. Autologous and allogeneic transplants for multiple myeloma. Semin Hematol 1995;32:31-44.
53. Mandelli F, Avvisati G, Amadori S, Boccadoro M, Gernone A, Lauta VM, et al. Maintenance treatment with recombinant interferon alfa 2b in patients with multiple myeloma responding to conventional induction therapy. N Engl J Med 1990;332:1430-4.
54. Avvisati G, Mandelli F. The role of interferon-α to the management of myelomatosis. Hematol Oncol Clin North Am 1992;16:395-405.
55. Westin J, Rodjer S, Turesson I, Cortelezzi A, Hjorth M, Zador G. Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study. Br J Haematol 1995;89:561-8.
56. Browman GP, Bergsagel D, Sicheri D, O'Reilly S, Wilson K, Rubin S, et al. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1995;13: 2354-60.
57. Ludwig H, Cohen AM, Polliack A, Huber H, Nachbur D, Senn HJ, et al. Interferon-alpha induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies. Ann Oncol 1995;6:467-76.
58. Salmon SE, Crowley JJ, Grogan TM, Finley P, Pugh RP, Barlogie B. Combination chemotherapy, glucocorticoids and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study. J Clin Oncol 1994;12: 2405-14.
59. Peest D, Deicher H, Coldewey R, Leo R, Bartl R, Bartels H, et al. A comparison of polychemotherapy and melphalan/ prednisone for primary remission induction, and interferon-alfa for maintenance treatment in multiple myeloma. Eur J Cancer 1995;31A:146-51.
60. Cunningham D, Powles R, Malpas J, Milan S, Meldrum M, Viner C, et al. A randomized trial of maintenance therapy with Intron-A following high-dose melphalan and ABMT in myeloma. Proc Am Soc Clin Oncol 1993;12:364.
61. Cooper MR, Dear K, McIntyre OR, Ozer H, Ellerton J, Canellos G, et al. A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B study. J Clin Oncol 1993;11:155-60.
62. Hjorth M, Westin J, Dahl IMS, Gimsing P, Hippe E, Holmberg E, et al., for the Nordic Myeloma Study Group. Interferon-α2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma: a randomized, controlled trial. Ann Intern Med 1996;124:212-22.
63. Wheatley K, on behalf of the Myeloma Trialists' Collaborative Group. The role of interferon as therapy for multiple myeloma: an overview of 24 randomized trials with over 4000 patients. Proc Am Soc Clin Oncol 1998;17:8a.